tiprankstipranks

2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma

2seventy Bio to discontinue enrollment in Phase 3 KarMMa-9 study of Abecma

2seventy bio (TSVT) announced that the company, in partnership with study sponsor Bristol Myers Squibb (BMY), will discontinue enrollment in its ongoing Phase 3 KarMMa-9 study evaluating Abecma with lenalidomide maintenance versus lenalidomide maintenance alone in patients with newly diagnosed multiple myeloma who have suboptimal response to autologous stem cell transplant. “With a greatly improved NDMM treatment landscape and following our rigorous review of the business case for the KarMMa-9 study, we have decided to discontinue enrollment in this Phase 3 study,” said Chip Baird, chief executive officer, 2seventy bio. “Abecma continues to show encouraging signs of growth with an expanded label in the third line and a differentiated safety profile. Consistent with our focus on capital allocation and creating value for all stakeholders, we anticipate this decision will conserve over $80 million in near-term expenditures and accelerate our path to breakeven in 2025. We will continue to look for ways to optimize our business for growth while remaining true to our mission of delivering more time for patients.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue